Nina Gotcheva

15.9k total citations
17 papers, 290 citations indexed

About

Nina Gotcheva is a scholar working on Cardiology and Cardiovascular Medicine, Surgery and Economics and Econometrics. According to data from OpenAlex, Nina Gotcheva has authored 17 papers receiving a total of 290 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Cardiology and Cardiovascular Medicine, 7 papers in Surgery and 4 papers in Economics and Econometrics. Recurrent topics in Nina Gotcheva's work include Cardiac Health and Mental Health (5 papers), Health Systems, Economic Evaluations, Quality of Life (4 papers) and Lipoproteins and Cardiovascular Health (4 papers). Nina Gotcheva is often cited by papers focused on Cardiac Health and Mental Health (5 papers), Health Systems, Economic Evaluations, Quality of Life (4 papers) and Lipoproteins and Cardiovascular Health (4 papers). Nina Gotcheva collaborates with scholars based in Bulgaria, Poland and United Kingdom. Nina Gotcheva's co-authors include Sabina A. Murphy, HD White, E. Braunwald, Elliot M. Antman, David Wood, Dirk De Bacquer, Kornelia Kotseva, Guy De Backer, Željko Reiner and Michel P. Hermans and has published in prestigious journals such as SHILAP Revista de lepidopterología, Journal of the American College of Cardiology and European Heart Journal.

In The Last Decade

Nina Gotcheva

17 papers receiving 283 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Nina Gotcheva Bulgaria 9 192 104 52 49 36 17 290
Sylvie Etienne France 8 289 1.5× 105 1.0× 37 0.7× 27 0.6× 33 0.9× 13 339
R. Collins United Kingdom 3 228 1.2× 85 0.8× 57 1.1× 24 0.5× 14 0.4× 5 296
Stuart Pocock United Kingdom 8 317 1.7× 94 0.9× 29 0.6× 29 0.6× 103 2.9× 20 380
Kadhim Sulaiman Oman 11 265 1.4× 67 0.6× 18 0.3× 26 0.5× 26 0.7× 27 355
José Javier Gómez-Barrado Spain 6 90 0.5× 97 0.9× 24 0.5× 11 0.2× 36 1.0× 51 192
Francisco Javier Chorro Spain 10 433 2.3× 42 0.4× 47 0.9× 41 0.8× 8 0.2× 12 482
F.W.A. Verheugt Netherlands 7 279 1.5× 102 1.0× 37 0.7× 10 0.2× 21 0.6× 28 348
Venkatesan Vidi United States 7 158 0.8× 53 0.5× 28 0.5× 35 0.7× 102 2.8× 12 351
Ali Shafiq United States 10 266 1.4× 92 0.9× 15 0.3× 26 0.5× 11 0.3× 34 341
Maarten Simoons Netherlands 7 306 1.6× 128 1.2× 18 0.3× 44 0.9× 12 0.3× 13 374

Countries citing papers authored by Nina Gotcheva

Since Specialization
Citations

This map shows the geographic impact of Nina Gotcheva's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nina Gotcheva with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nina Gotcheva more than expected).

Fields of papers citing papers by Nina Gotcheva

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nina Gotcheva. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nina Gotcheva. The network helps show where Nina Gotcheva may publish in the future.

Co-authorship network of co-authors of Nina Gotcheva

This figure shows the co-authorship network connecting the top 25 collaborators of Nina Gotcheva. A scholar is included among the top collaborators of Nina Gotcheva based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nina Gotcheva. Nina Gotcheva is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Szarek, Michael, Marco Valgimigli, Md. Shahidul Islam, et al.. (2023). Lipoprotein(a) and the Effect of Alirocumab on Revascularization After Acute Coronary Syndrome. Canadian Journal of Cardiology. 39(10). 1315–1324. 3 indexed citations
2.
Gotcheva, Nina, et al.. (2023). NGAL as Biomarker of Clinical and Subclinical Damage of Kidney Function after Coronary Angiography. Diagnostics. 13(6). 1180–1180. 1 indexed citations
3.
Bacquer, Dirk De, Catriona Jennings, Erkin М Мirrakhimov, et al.. (2021). Potential for optimizing management of obesity in the secondary prevention of coronary heart disease. European Heart Journal - Quality of Care and Clinical Outcomes. 8(5). 568–576. 9 indexed citations
4.
Vinereanu, Dragoş, Д. А. Напалков, Jutta Bergler‐Klein, et al.. (2020). Patient perception of anticoagulant treatment for stroke prevention (RE-SONANCE study). Open Heart. 7(1). e001202–e001202. 6 indexed citations
5.
Vladimirov, G., et al.. (2020). Neutrophil Gelatinase-Associated Lipocalin (NGAL) predict higher risk of serious renal dysfunction in patients with CI-AKI. European Heart Journal. 41(Supplement_2). 4 indexed citations
6.
Bacquer, Dirk De, Peter Ueda, Željko Reiner, et al.. (2020). Prediction of recurrent event in patients with coronary heart disease: the EUROASPIRE Risk Model. European Journal of Preventive Cardiology. 29(2). 328–339. 29 indexed citations
7.
Szarek, Michael, Philippe Gabríel Steg, Deepak L. Bhatt, et al.. (2019). Alirocumab Reduces Total Hospitalizations and Increases Days Alive and Out of Hospital in the ODYSSEY OUTCOMES Trial. Circulation Cardiovascular Quality and Outcomes. 12(11). e005858–e005858. 9 indexed citations
8.
9.
Vladimirov, G., et al.. (2016). TCT-385 The role of Neutrophil Gelatinase-Associated Lipocalin (NGAL) for evaluation of kidney function in patients undergoing coronary angiography. Journal of the American College of Cardiology. 68(18). B157–B157. 1 indexed citations
10.
Backer, Guy De, Dirk De Bacquer, Lars Rydén, et al.. (2016). Lifestyle and risk factor management in people at high cardiovascular risk from Bulgaria, Croatia, Poland, Romania and the United Kingdom who participated in both the EUROASPIRE III and IV primary care surveys. European Journal of Preventive Cardiology. 23(15). 1618–1627. 17 indexed citations
11.
Chiang, Chern‐En, Jean Ferrières, Nina Gotcheva, et al.. (2015). Suboptimal Control of Lipid Levels: Results from 29 Countries Participating in the Centralized Pan-Regional Surveys on the Undertreatment of Hypercholesterolaemia (CEPHEUS). Journal of Atherosclerosis and Thrombosis. 23(5). 567–587. 48 indexed citations
12.
Mega, Jessica L., Eugene Braunwald, Stephen D. Wiviott, et al.. (2013). Comparison of the Efficacy and Safety of Two Rivaroxaban Doses in Acute Coronary Syndrome (from ATLAS ACS 2–TIMI 51). The American Journal of Cardiology. 112(4). 472–478. 35 indexed citations
13.
Gotcheva, Nina, et al.. (2013). Assessment of lipid-lowering treatment in Bulgaria — The CEPHEUS study. SHILAP Revista de lepidopterología. 8(5). 627–637. 3 indexed citations
14.
Vassilev, Dobrin, Robert Gil, Bon‐Kwon Koo, et al.. (2012). The determinants of side branch compromise after main vessel stenting in coronary bifurcation lesions.. PubMed. 70(10). 989–97. 10 indexed citations
15.
Smedt, Delphine De, Kornelia Kotseva, Dirk De Bacquer, et al.. (2012). Cost-effectiveness of optimizing prevention in patients with coronary heart disease: the EUROASPIRE III health economics project. European Heart Journal. 33(22). 2865–2872. 46 indexed citations
16.
17.
Georgiev, B., et al.. (2004). USE OF CALCIUM CHANNEL BLOCKERS IN HYPERTENSION TREATMENT IN PRIMARY CARE. Journal of Hypertension. 22(Suppl. 1). S198–S198. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sylvie Etienne Breakdown of academic impact, for papers by R. Collins Breakdown of academic impact, for papers by Stuart Pocock Breakdown of academic impact, for papers by Kadhim Sulaiman Breakdown of academic impact, for papers by José Javier Gómez-Barrado Breakdown of academic impact, for papers by Francisco Javier Chorro Breakdown of academic impact, for papers by F.W.A. Verheugt Breakdown of academic impact, for papers by Venkatesan Vidi Breakdown of academic impact, for papers by Ali Shafiq Breakdown of academic impact, for papers by Maarten Simoons
Rankless by CCL
2026